Ipsen’s long-standing expertise spans the value chain, from active principle to finished product to the patient, with special expertise in gastrointestinal (GI) disorders, neurodegenerative pathologies and rheumatology, and a constantly expanding portfolio.
Once primarily driven by physicians’ prescriptions, the origination of Ipsen’s Primary Care business has evolved in recent years into a mix of physicians’ prescriptions, recommendations by pharmacists and patients’ demand originated through direct communication.
Recently renamed “Ipsen Consumer Healthcare”, the division’s identity is now fully aligned with both the reality of our day-to-day activity worldwide and the development that we are envisioning for the coming years.
Ipsen’s Consumer Healthcare division puts the patient first by designing simple, safe, effective
and accessible treatments – an essential approach at a time when consumers are playing an increasingly active role in making their own treatment choices and are looking for convenient, ready-to-use solutions.
In 2016, the division continued its strategy of reinforcing its gastrointestinal portfolio, expanding its capacity and portfolio in the over-the-counter (OTC) segment and expanding its geographical reach.
Three major actions were taken to these ends in 2016 and early 2017. First, a license and distribution agreement with the Swedish firm Probi for the commercialization of the probiotic strain Lactobaci l lus plantarum 299v
(LP299V®). This compound has shown strong clinical evidence for reduction of signs and symptoms of irritable bowel syndrome in adults.
Second, the acquisition from Sanofi of five consumer healthcare products in certain European territories. The most important is Prontalgine®, an analgesic for the treatment of moderate to severe pain. The portfolio also includes Buscopan®, an antispasmodic; Suppositoria Glycerini, a laxative; and the expectorants Mucothiol® and Mucodyne®. This transaction further accelerates the development of our Consumer Healthcare business and our conversion to an OTx (combined prescription and over-the-counter) business model.
The third event was the acquisition of an equity stake in Akkadeas Pharma, a privately-held consumer healthcare company in Italy, with an option to take control of the company in the future. Akkadeas Pharma’s diversified portfolio includes probiotics, medical devices and food supplements.
It will become Ipsen’s Italian distributor for Smecta® (Diosmectal®).
Smecta®, Ipsen’s trusted flagship product, is primarily indicated for the symptomatic treatment of acute diarrhea. A ready-to-use liquid solution is also available now in some countries. Other members of this family include Smebiocta® – LP299V®, the first probiotics launched by Ipsen which provides an innovative solution for GI disorders.
The GI portfolio also includes Forlax®, an osmotic laxative; Fortrans®, a colon-cleansing solution; and Eziclen®/Izinova®, a second-generation bowel-cleansing preparation.
Tanakan® is a standardized, patented ginkgo biloba extract (EGb 761®) for the symptomatic treatment of such cognitive disorders as memory deficit and concentration disturbances in the elderly, and for vertigo and tinnitus.
Adenuric® is a therapy for the management of gout, an inflammatory form of arthritis caused by elevated levels of uric acid in the blood.
Sales in consumer healthcare in 2016
(19.7% of sales in 2016)